Latest Pseudomembranous colitis Stories
Results indicate vaccine generates an immune response against key toxins in volunteers and establish dosing for Phase III BOSTON, May 19, 2014 /PRNewswire/ -- Sanofi Pasteur, the vaccines
A pilot study by Massachusetts General Hospital (MGH) investigators may lead to greater availability and acceptability of an unusual treatment for a serious medical problem – use of fecal material from healthy donors to treat recurrent diarrhea caused by the Clostridium difficile (C. difficile) bacteria.
WALTHAM, Mass., Jan. 29, 2014 /PRNewswire/ -- IMDx announced today that the artus C.
Vaccine Journal Publishes Study Documenting the Dose-Dependent Effect of HOWARU® Restore Kantvik, Finland (PRWEB) December 12, 2013 A study to investigate
University of Cincinnati (UC) researchers have found that an imbalance in the regulation of certain T cells—the cells in the body that fight off infection or attack the system in certain autoimmune diseases—may put certain people at a higher risk of having recurrent cases of Clostridium difficile, or C. Diff, infection.
Clostridium difficile, also known as "CDF/cdf", or "C. diff", is a Gram-positive bacteria of the genus Clostridium that causes severe diarrhea and other intestinal disease when competing bacteria in the gut flora are wiped out by antibiotics. They are anaerobic, spore-forming rods and is the most serious cause of antibiotic-associated diarrhea and potentially to pseudomembranous colitis. C. difficile bacteria naturally resides in the gut of a small percentage of the adult population. Others...
- A poem in which the author retracts something said in an earlier poem.